Rapid Micro Biosystems, Inc.

NASDAQ:RPID

Medical - Devices

Healthcare
$1.11 +1.49%

+$0.03 today

Market cap
$50.31M
Beta
1.46
P/E (TTM)
-1.5
EPS (TTM)
-$1.10
52W Low $1.66High $4.94

Volume 0.17M

Average 0.18M

RPID Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Rapid Micro Biosystems, Inc.NASDAQ: RPID

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit dips below year-ago levels

Q1 FY2026 gross profit of $371K fell 8.2% year over year, behind the +134.5% change in trailing-twelve-month gross profit.

Context

  • Gross profit amounted to 22.7% of revenue in FY2025, up 22.3 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.2% toward the trailing-twelve-month pace of +134.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$371K+212.8% QoQ
Last fiscal yearDec 2025
$7.61M+7079.8% YoY
LTMMar 2026
$4.26M+134.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.2%——
1 year+7079.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
7.61M USD
Year-over-year change
+7079.8%

Gross Profit vs competitors

How RPID compares with its peers on the latest reported figures

  • RPID's LTM Mar 2026 gross profit of $4.26M is the 5th highest of the 9 companies compared; the peer median is $8.97M.
  • Its year-over-year change of +134.5% is the highest of 8, against a peer median of -3.9%.
  • Gross profit amounts to 12.4% of revenue for RPID, versus a peer median of 48.1%.
RPID Competitors Peer median
Gross Profit for RPID and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCELAVITA Medical, Inc.LTM Mar 2026$58.86M -3.9%+27.5%81.4%
OWLTOwlet, Inc.LTM Mar 2026$54.45M +23.4%+31.9%50.9%
LNSRLENSAR, Inc.LTM Mar 2026$26.15M -3.4%+10.8%45.3%
APYXApyx Medical CorporationLTM Mar 2026$18.04M -26.0%-13.2%32.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$4.26M +134.5%—12.4%
SERASera Prognostics, Inc.LTM Mar 2026-$109K -1190.0%—191.2%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$129K ———
VANIVivani Medical, Inc.LTM Mar 2026-$130K -46.1%——
LUCDLucid Diagnostics Inc.LTM Mar 2026-$2.06M +27.2%—40.0%
Peer median (excluding RPID) $8.97M-3.9%+19.1%48.1%

Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.23M17.13M22.52M28.05M33.59M
Cost of Revenue30.97M25.67M28M28.16M25.98M
Gross Profit(7.74M)(8.54M)(5.49M)(109K)7.61M
Gross Margin-33.3%-49.8%-24.4%-0.4%22.7%
Research & Development9.78M12.87M12.82M14.6M13.6M
Selling, General & Admin29.71M41.81M38.26M35.21M34.84M
Operating Expenses39.49M54.68M51.08M49.81M55M
Depreciation & Amortization1.53M2.84M3.11M3.36M3.25M
EBITDA(69.25M)(58.55M)(49.33M)(43.51M)(42.74M)
EBITDA Margin-298.1%-341.7%-219.1%-155.1%-127.3%
Operating Income(47.23M)(63.22M)(56.56M)(49.92M)(47.39M)
Operating Margin-203.3%-369.0%-251.2%-178.0%-141.1%
Interest Income01.78M4.21M3.16M1.51M
Interest Expense2.65M0001.09M
Other Income / Expenses(26.2M)1.84M4.13M3.05M309K
Income Before Tax(73.43M)(61.38M)(52.44M)(46.87M)(47.08M)
Pre-Tax Margin-316.1%-358.3%-232.9%-167.1%-140.2%
Income Tax Expense91K(576K)31K22K40K
Net Income(73.52M)(60.81M)(52.47M)(46.89M)(47.12M)
Net Margin-316.5%-354.9%-233.0%-167.2%-140.3%
EPS (Basic)(1.88)(1.43)(1.22)(1.08)(1.05)
EPS (Diluted)(1.88)(1.43)(1.22)(1.08)(1.05)
Weighted Avg Shares41.47M42.45M43.02M43.58M44.68M
Weighted Avg Shares (Diluted)41.47M42.45M43.02M43.58M44.68M

Rapid Micro Biosystems, Inc.

NASDAQ:RPID

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.